Akari Therapeutics Posts $17.3M Net Loss, Shifts R&D Focus to ADC Pipeline
Summary
Akari Therapeutics reported a significant net loss of $17.3 million in its 10-K filing, alongside a 60% reduction in R&D expenses as it strategically pivots its pipeline. The company is now prioritizing its PH1-based ADC program, initiating GMP manufacturing and targeting a Phase 1 trial for Q1 2027, while suspending legacy nomacopan programs. This financial update follows the company's recent 1-for-40 reverse stock split, underscoring its challenging financial position. The substantial net loss relative to its micro-cap valuation, coupled with the complete reprioritization of its pipeline, represents a material change in the company's operational and financial outlook. Investors should monitor the progress of the ADC program and details of the 'near-term financing arrangements' mentioned, which could involve further dilution.
At the time of this announcement, AKTX was trading at $0.12 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.1M. The 52-week trading range was $0.12 to $1.58. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Wiseek News.